DE60322748D1 - Xanthinderivate als a2b-adenosinrezeptorantagonisten - Google Patents
Xanthinderivate als a2b-adenosinrezeptorantagonistenInfo
- Publication number
- DE60322748D1 DE60322748D1 DE60322748T DE60322748T DE60322748D1 DE 60322748 D1 DE60322748 D1 DE 60322748D1 DE 60322748 T DE60322748 T DE 60322748T DE 60322748 T DE60322748 T DE 60322748T DE 60322748 D1 DE60322748 D1 DE 60322748D1
- Authority
- DE
- Germany
- Prior art keywords
- receptor antagonists
- adenosine receptor
- xanthine derivatives
- xanthine
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2003/014085 WO2004106337A1 (en) | 2003-05-06 | 2003-05-06 | Xanthine derivatives as a2b adenosine receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60322748D1 true DE60322748D1 (de) | 2008-09-18 |
Family
ID=33488737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60322748T Expired - Lifetime DE60322748D1 (de) | 2003-05-06 | 2003-05-06 | Xanthinderivate als a2b-adenosinrezeptorantagonisten |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1622908B1 (de) |
JP (1) | JP2006515316A (de) |
CN (1) | CN100590125C (de) |
AT (1) | ATE403656T1 (de) |
AU (1) | AU2003249604B2 (de) |
CA (1) | CA2524778C (de) |
CY (1) | CY1108457T1 (de) |
DE (1) | DE60322748D1 (de) |
DK (1) | DK1622908T3 (de) |
ES (1) | ES2311759T3 (de) |
HK (1) | HK1092137A1 (de) |
MX (1) | MXPA05011860A (de) |
NZ (1) | NZ543416A (de) |
PT (1) | PT1622908E (de) |
SI (1) | SI1622908T1 (de) |
WO (1) | WO2004106337A1 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2301937A1 (de) * | 2005-06-16 | 2011-03-30 | Cv Therapeutics, Inc. | A2b Adenosinrezeptorantagonist-Prodroge |
ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
EP1989210A2 (de) * | 2006-03-02 | 2008-11-12 | Cv Therapeutics, Inc. | A2a-adenosinrezeptorantagonisten |
WO2009088518A1 (en) * | 2008-01-11 | 2009-07-16 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for the treatment of cancer |
US8871751B2 (en) | 2008-01-18 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer |
AU2009230679B2 (en) * | 2008-03-26 | 2013-07-18 | Advinus Therapeutics Pvt. Ltd. | Heterocyclic compounds as adenosine receptor antagonist |
WO2009157938A1 (en) * | 2008-06-26 | 2009-12-30 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for treating cancer |
EP2405917B1 (de) * | 2009-03-13 | 2014-04-23 | Advinus Therapeutics Private Limited | Substituierte kondensierte pyrimidin-verbindungen |
JP5843778B2 (ja) | 2009-11-09 | 2016-01-13 | アドヴィナス・セラピューティックス・リミテッド | 置換縮合ピリミジン化合物、その調製およびその使用 |
AU2011303420B2 (en) | 2010-09-13 | 2014-03-20 | Impetis Biosciences Ltd. | Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications |
NZ711718A (en) * | 2013-03-15 | 2020-05-29 | Hydra Biosciences Llc | Substituted xanthines and methods of use thereof |
ES2580702B1 (es) | 2015-02-25 | 2017-06-08 | Palobiofarma, S.L. | Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina |
WO2017106352A1 (en) | 2015-12-14 | 2017-06-22 | Raze Therapeutics, Inc. | Caffeine inhibitors of mthfd2 and uses thereof |
US11045472B2 (en) * | 2017-05-05 | 2021-06-29 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
CN112218867B (zh) * | 2018-03-05 | 2023-11-21 | 泰昂治疗公司 | 腺苷受体拮抗剂及其用途 |
MX2021008094A (es) | 2019-01-11 | 2021-09-21 | Omeros Corp | Metodos y composiciones para el tratamiento del cancer. |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8510758D0 (en) * | 1985-04-27 | 1985-06-05 | Wellcome Found | Compounds |
DE8817122U1 (de) * | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 6507 Ingelheim, De | |
JPH06102662B2 (ja) * | 1989-09-01 | 1994-12-14 | 協和醗酵工業株式会社 | キサンチン誘導体 |
WO1995011681A1 (en) * | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Human adenosine receptor antagonists |
DE19535504A1 (de) * | 1995-09-25 | 1997-03-27 | Bayer Ag | Substituierte Xanthine |
US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
DK0956855T3 (da) * | 1998-04-24 | 2003-07-14 | Leuven K U Res & Dev | Immunhæmmende effekter af 8-substituerede xanthin-derivater |
US6545002B1 (en) * | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
DE60206756T2 (de) * | 2001-06-29 | 2006-07-13 | CV Therapeutics, Inc., Palo Alto | Purin derivate als a2b adenosin rezeptor antagonisten |
PL370207A1 (en) * | 2001-11-09 | 2005-05-16 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists |
NZ528591A (en) * | 2002-02-01 | 2006-11-30 | King Pharmaceuticals Res & Dev | 8-heteroaryl xanthine adenosine A2B receptor antagonists and their pharmaceutical use |
-
2003
- 2003-05-06 DK DK03817096T patent/DK1622908T3/da active
- 2003-05-06 PT PT03817096T patent/PT1622908E/pt unknown
- 2003-05-06 AT AT03817096T patent/ATE403656T1/de active
- 2003-05-06 CN CN03826411A patent/CN100590125C/zh not_active Expired - Fee Related
- 2003-05-06 ES ES03817096T patent/ES2311759T3/es not_active Expired - Lifetime
- 2003-05-06 WO PCT/US2003/014085 patent/WO2004106337A1/en active Application Filing
- 2003-05-06 JP JP2005500296A patent/JP2006515316A/ja active Pending
- 2003-05-06 SI SI200331355T patent/SI1622908T1/sl unknown
- 2003-05-06 AU AU2003249604A patent/AU2003249604B2/en not_active Ceased
- 2003-05-06 NZ NZ543416A patent/NZ543416A/en not_active IP Right Cessation
- 2003-05-06 DE DE60322748T patent/DE60322748D1/de not_active Expired - Lifetime
- 2003-05-06 CA CA2524778A patent/CA2524778C/en not_active Expired - Fee Related
- 2003-05-06 MX MXPA05011860A patent/MXPA05011860A/es active IP Right Grant
- 2003-05-06 EP EP03817096A patent/EP1622908B1/de not_active Expired - Lifetime
-
2006
- 2006-08-07 HK HK06108745.5A patent/HK1092137A1/xx not_active IP Right Cessation
-
2008
- 2008-10-27 CY CY20081101212T patent/CY1108457T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ATE403656T1 (de) | 2008-08-15 |
CN100590125C (zh) | 2010-02-17 |
CY1108457T1 (el) | 2014-04-09 |
NZ543416A (en) | 2009-01-31 |
EP1622908A1 (de) | 2006-02-08 |
HK1092137A1 (en) | 2007-02-02 |
CN1771250A (zh) | 2006-05-10 |
ES2311759T3 (es) | 2009-02-16 |
DK1622908T3 (da) | 2008-11-17 |
AU2003249604A1 (en) | 2005-01-21 |
CA2524778C (en) | 2013-01-29 |
PT1622908E (pt) | 2008-11-14 |
AU2003249604B2 (en) | 2011-06-30 |
MXPA05011860A (es) | 2006-02-17 |
EP1622908B1 (de) | 2008-08-06 |
SI1622908T1 (sl) | 2008-12-31 |
JP2006515316A (ja) | 2006-05-25 |
WO2004106337A1 (en) | 2004-12-09 |
CA2524778A1 (en) | 2004-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1092137A1 (en) | Xanthine derivatives as a2b adenosine receptor antagonists | |
ATE461932T1 (de) | Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors | |
CY2017015I1 (el) | ΕΤΕΡΟΑΡΥΛΟ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΠΥΡΡΟΛΟ[2,3-b]ΠΥΡΙΔΙΝΕΣ ΚΑΙ ΠΥΡΡΟΛΟ[2,3-b]ΠΥΡΙΜΙΔΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ JANUS | |
WO2003042214A3 (en) | A2b adenosine receptor antagonists | |
WO2005105803A3 (en) | Purine derivatives as a1 adenosine receptor antagonists | |
ATE387446T1 (de) | Pyrido(2,3-d)pyrimidin-2,4-diamine als pde-2- inhibitoren | |
DE122012000043I1 (de) | Pyrrolo[2,3-B]pyridinderivate als proteinkinaseinhibitoren. | |
ATE384053T1 (de) | Triazolderivate als tachykininrezeptor- antagonisten | |
WO2005021548A3 (en) | Substituted 8-heteroaryl xanthines | |
ATE538123T1 (de) | 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors | |
DE60313872D1 (de) | Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen | |
DK2272517T3 (da) | Orto-kondenserede pyridin- og pyrimidinderivater (f.eks. puriner) som proteinkinaseinhibitorer | |
DK1824856T3 (da) | 2,4 (4,6)-pyrimidinderivater | |
ATE422198T1 (de) | Arylsulfonylnaphthalinderivate als 5ht2a- antagonisten | |
DE60332396D1 (de) | PYRAZOLOi3,4-B PYRIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS PHOSPHODIESTERASE INHIBITOREN | |
DE602006007556D1 (de) | Heteroarylsulfonylstilbene als 5-ht2a-antagonisten | |
ATE360632T1 (de) | Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate | |
ATE432282T1 (de) | 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten | |
DE602005007181D1 (de) | 1h-thieno 2,3-c-pyrazol-derivate als kinase-i-hemmer | |
BRPI0512547A (pt) | pirimidinas | |
ATE452892T1 (de) | Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate | |
DE602004018637D1 (de) | A2a-adenosinrezeptorantagonisten | |
DK1608653T3 (da) | Substituerede 8-perfluoroalkyl-6,7,8,9- tetrahydropyrimido (1,2-a) pyrimidin-4-on derivater | |
DE60317684D1 (de) | SUBSTITUIERTE 2,4-DIHYDROPYRROLOc3,4BÜCHINOLIN-9-ONDERIVATE, DIE SICH ALS PHOSPHODIESTERASEINHIBITOREN EIGNEN | |
ATE394402T1 (de) | Kondensierte purinderivate als a1- adenosinrezeptorantagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |